Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients

BACKGROUND: Cisplatin-based chemotherapy was previously considered as the standard adjuvant therapy for improved overall survival (OS) in patients with non-small cell lung cancer (NSCLC) after surgery. However, the benefit was limited due to high risks of recurrence and adverse events. In the presen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Chen, Rui-Lian, Sun, Ling-Ling, Cao, Yang, Chen, Han-Rui, Zhou, Jing-Xu, Gu, Chu-Ying, Zhang, Ying, Wang, Si-Yu, Hou, Wei, Lin, Li-Zhu
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8071858/
https://ncbi.nlm.nih.gov/pubmed/33912453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.629394
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados